thought call
larger expect season headwind across base-hiv hcv
busi like prompt investor skeptic thesi regard rebound
top- bottom-lin trajectori remain intact trough earn give
rise return growth start hcv revenu continu compress
note price larg stabil patient start normal
indic moder declin move forward gener tdf impact hiv
sale uptak taf regimen remain robust consist recent
analyseswith initi indic biktarvi like becom domin fdc
global see gilead scienc updat global hiv trend gilead could
help investor better quantifi neg inventori trend hiv
stabl guidanc impli rebound outsid anti-vir see
encourag progress yescarta upsid sign us oper
start scale center author track treat elig patient
potenti upsid pipelin nash program
filgotinib although think deal later-stag asset would help drive
investor interest continu encourag gilead return-to-growth stori
driven hiv cart maintain ow lower pt given trend
pipelin updat among key catalyst capabl drive near-term growth
continu expect eu approv biktarvi yescarta phase filgotinib
ra trial fulli enrol data like start enrol
phase selonsertib nash studi patient ahead schedul
readout track potenti support regulatori submiss
adjust estim modestli adjust revenu acceler
hcv hiv tdf-fdc declin off-set posit outlook taf uptak
result in-lin pre-earn consensu upper end compani
product sale guidanc oper expens move line
result estim non-gaap ep remain
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight gilead move beyond
declin hcv franchis diversifi
oncolog car-t creat intermedi term
visibl could return growth hiv
stabl bictegravir potenti drive
share gain car-t earli stage technolog
hematolog expans solid tumor ad
valu
modest declin hcv robust uptak
taf regimen hiv pipelin success non-
virolog agent larg discount share
would drive upsid de-risk axi-cel addit
hematolog success solid tumor
price pressur drive faster declin hcv
diminish cash flow therebi affect abil
busi develop hiv gener
larger impact expect new taf regimen
experi limit uptak car-t fail expand
price target vs prior base sum-of-the-part approach
estim npv valu key franchis use wacc vs prior
differ growth rate major product assumpt valu hiv
vs prior hcv vs prior car-t
unchang product unchang pipelin
unchang net cash unchang
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
